ClinicalTrials.gg
CompletedNCT05220878Updated Mar 6, 2024

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

A Phase 3 interventional study of GNR-069 and Nplate in Idiopathic Thrombocytopenic Purpura, sponsored by AO GENERIUM. Completed at 18 sites in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by AO GENERIUM · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2021, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
8th of 29
160 · median 62
Started
2021
the only one that year
Phase 3
13 of 29
1 open now
Registered
22nd of 29
by date
Lead sponsor
2 of 29
AO GENERIUM

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 13 in phase 3, and was the 22nd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

It is a phase III multicenter randomized double-blinded comparative study of clinical efficacy and safety of GNR-069 and Nplate in patients with idiopathic thrombocytopenic purpura

Read the detailed description

The drug GNR-069(JSC "GENERIUM", Russia) is biosimilar to the original drug Nplate. This study is aimed to compare the clinical efficacy and safety of the drug GNR-069 and the drug Nplate to register of the drug GNR-069 in the Russian Federation for therapy in patients with idiopathic thrombocytopenic purpura (ITP). The study also provides for the evaluation of pharmacokinetic parameters and immunogenicity.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura

Keywords

  • Idiopathic thrombocytopenic purpura
  • ITP
  • Thrombocytopenia
  • Thrombocytopoiesis
  • Bleeding
  • Hemorrhagic syndrome
  • Petechial rash
  • Ecchymosis
  • Fc-peptide
  • Recombinant DNA technology
  • Thrombopoietin receptors
  • Platelet formation
  • Fc fragment of human immunoglobulin IgG 1
  • Low platelet count
  • ITP treatment
  • Platelets
  • Haemorrhage
  • Platelet destruction
  • Impaired thrombopoiesis
  • Megakaryocytes
  • Autoantibodies
  • Splenectomy
  • Cytotoxic
  • T cells
  • Thrombopoietin receptor agonists
  • TPO-RAs
  • romiplostim
  • Nplate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written Form to participate in the study;
  2. Men and women aged 18-75 years inclusive at the time of signing the Informed Consent Form;
  3. Documented diagnosis of ITP with a disease duration of more than 12 months from the moment of confirmation of the diagnosis by bone marrow aspirate or results;
  4. A. For patients who have not had splenectomy:

    • established absence/loss of response to therapy with at least one drug of fist-line treatment for ITP (which include GCs an IVIG); OR
    • the occurrence of side effects during the course of therapy with the drug of the fist-line, making it impossible to use it further;

    B. For patients who underwent splenectomy:

    • loss/lack of response to splenectomy;
  5. Thrombocytopenia ≥30.0 x 109/L - \<50.0 x 109/L with severe hemorrhagic syndrome or thrombocytopenia \<30.0 x 109/l, regardless of the presence of hemorrhagic syndrome, according to the results of count conducted in a local laboratory for 7 days before the start of therapy with or reference drug;
  6. Patients receiving GCs, azathioprine and danazole should receive these drugs in a maintenance dose for at least 4 weeks before starting therapy with investigational or reference drug;
  7. Consent of study participants with preserved childbearing function to use reliable methods of (a combination of at least two methods, including 1 barrier method, for example, the use of a condom and spermicide) from the moment of signing the Informed Consent Form and 3 months after the last administration of investigational or reference drug.

Exclusion criteria

Exclusion Criteria:

  1. to the components of or reference drug or E. coli proteins ;
  2. Unresolved severe hemorrhagic syndrome requiring emergency treatment at the time of initiation of study or reference drug therapy ;
  3. Fisher-Evans Syndrome;
  4. Conditions with a high risk of thromboembolic complications ;
  5. Myelodysplastic syndrome and/or bone marrow transplantation in anamnesis;
  6. Deviations of clinical and laboratory parameters according to the results of studies of blood samples taken during the screening period;
  7. Positive test results for , , or (HIV);
  8. Pregnancy or breastfeeding;
  9. Use of drugs:

    • romiplostim used less than 3 weeks before treatment with study or reference drug;
    • IVIG - less than 2 weeks prior to initiation of study or reference drug therapy;
    • eltrombopag - used less than 2 weeks before treatment with study or reference drug, or planned to use eltrombopag while the patient is participating in this study;
    • rituximab - used less than 14 weeks before treatment with study or reference drug, or planned to use rituximab while the patient is enrolled in this study;
    • cyclophosphamide, cyclosporine, vincristine, vinblastine and other drugs used to treat ITP not listed above and not included in the list of drugs approved for use during the study - use less than 8 weeks before the start of therapy with the study or reference drug or the use of any of these drugs is planned during the patient's participation in this study;
    • preparations of any hematopoietic growth factors - use less than 8 weeks before the start of therapy with an investigational or reference drug;
    • Influenza vaccines - less than 21 days prior to start of treatment with study or reference drug;
    • vaccines to prevent novel coronavirus disease (COVID-19) - completion of the vaccination program less than 21 days prior to the start of study or reference drug therapy;
    • other vaccines - less than 8 weeks prior to start of treatment with study or reference drug;
  10. Splenectomy within 12 weeks prior to screening;
  11. Participation in any clinical trials and/or use of unregistered drugs within 4 weeks prior to screening or 5 drug half-lives (whichever is greater);
  12. Any other disease or condition that, in the opinion of the investigator, may preclude the patient from participating in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    GNR-069

    Main group (80 patients) - multiple weekly subcutaneous injections of GNR-069, doses are calculated individually.

    Biological: GNR-069

  • Active comparator
    Nplate

    Control group (80 patients) - multiple weekly subcutaneous injections of Nplate, doses are calculated individually.

    Biological: Nplate

Interventions

  • BiologicalGNR-069

    Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.

    Also known as: romiplostim

  • BiologicalNplate

    Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.

    Also known as: romiplostim

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving sustained response to treatment

    A sustained response to treatment is defined as the number of platelets ≥ 50.0 x 109/L for at least 9 out of 12 consecutive visits during the treatment period with the study or reference drug.

    Time frame: 26 weeks

Secondary outcomes

  1. Proportion of patients who achieve stable platelet count during treatment with investigational or reference drug

    Stable platelet count is defined as the number of platelets ≥ 50.0 x 109/L for at least 4 consecutive weeks without dose adjustment.

    Time frame: 26 weeks

  2. Time from initiation of therapy with investigational or reference drug to reaching a stable platelet count

    Time frame: 26 weeks

  3. Number of cases of emergency therapy for severe hemorrhagic syndrome during the treatment period, starting from the second week of therapy with the investigational or reference drug

    Time frame: 25 weeks

  4. Number of clinically significant bleeding episodes during the treatment period, starting from the second week of therapy with investigational or reference drug

    Bleeding episode ≥ Grade 2 according to CTCAE version 5.0 is considered clinically significant

    Time frame: 26 weeks

  5. Change in ITP-specific bleeding assessment tool (ITP-BAT) scores at last visit from baseline at screening

    Time frame: 26 weeks

  6. Proportion of patients with no/loss of response to treatment with investigational or reference drug

    Time frame: 26 weeks

  7. Proportion of patients receiving approved ITP prophylactic drugs (glucocorticosteroids, azathioprine, danazol) in this study at the time of randomization

    Time frame: 26 weeks

07

Study locations

18 sites
  • State Budgetary Institution of Healthcare Irkutsk awarded the "Sign of Honor" Order Regional Clinical Hospital
    Irkutsk, Irkutsk Region 664079, Russian Federation
  • State Budgetary Health Institution of the Kaluga Region "Kaluga Regional Clinical Hospital"
    Kaluga, Kaluga Region 248007, Russian Federation
  • State Autonomous Healthcare Institution "Kuzbass Clinical Hospital named after S.V. Belyaev"
    Kemerovo, Kemerovo Region 650066, Russian Federation
  • State budgetary institution of health care of the Nizhny Novgorod region "Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko"
    Nizhny Novgorod, Nizhny Novgorod Region 603126, Russian Federation
  • Llc "Medis"
    Nizhny Novgorod, Nizhny Novgorod Region 603137, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Novosibirsk State Medical University" of the Ministry of Health of the Russian Federation
    Novosibirsk, Novosibirsk Region 630091, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation
    Ufa, Republic Of Bashkortostan 450008, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation
    Rostov-on-Don, Rostov Region 344022, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation
    Samara, Samara Region 443099, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of the Russian Federation
    Saratov, Saratov Region 410012, Russian Federation
  • State Health Institution of the Tula Region "Tula Regional Clinical Hospital"
    Tula, Tula Region 300053, Russian Federation
  • Municipal budgetary institution "Central City Hospital No. 7"
    Ekaterinburg, 620137, Russian Federation
  • State Budgetary Institution of Healthcare of the city of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov" Department of Health of the city of Moscow.
    Moscow, 111123, Russian Federation
  • Federal State Budgetary Institution "National Medical Research Center for Hematology" of the Ministry of Health of the Russian Federation
    Moscow, 125167, Russian Federation
  • State budgetary health care institution of the city of Moscow "Clinical Hospital named after S.P. Botkin" of the Department of Health of the city of Moscow
    Moscow, 125284, Russian Federation
  • State budgetary health care institution of the city of Moscow "City Clinical Hospital named after V.V. Veresaev of the Department of Health of the City of Moscow"
    Moscow, 127644, Russian Federation
  • State Budgetary Health Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
    Moscow, 129110, Russian Federation
  • Federal State Budgetary Institution "National Medical Research Center named after V.A. Almazov" of the Ministry of Health of the Russian Federation
    Saint Petersburg, 197341, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2023, 23 months.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 23 months is close to that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2022
First posted
Feb 2, 2022
StartActual
Sep 9, 2021
Primary completionActual
Aug 22, 2023
CompletionActual
Oct 19, 2023
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05220878
Lead sponsor
AO GENERIUM
Responsible party
Sponsor
First posted
Feb 2, 2022
Start date
Sep 9, 2021
Primary completion
Aug 22, 2023
Completion
Oct 19, 2023
Last update
Mar 6, 2024

Study contacts

Oksana A. Markova, MD, MSc
study chair · AO GENERIUM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion